Mokrysheva N, Eremkina A, Mirnaya S, Krupinova J, Voronkova I, Kim I
Probl Endokrinol (Mosk). 2021; 67(4):94-124.
PMID: 34533017
PMC: 9753843.
DOI: 10.14341/probl12801.
Song A, Zhao H, Yang Y, Liu S, Nie M, Wang O
J Endocrinol Invest. 2021; 44(8):1667-1677.
PMID: 33453021
DOI: 10.1007/s40618-020-01473-5.
Cakir B, Burcak Polat S, Kilic M, Ozdemir D, Aydin C, Sungu N
Arch Endocrinol Metab. 2016; 60(6):537-544.
PMID: 27901181
PMC: 10522169.
DOI: 10.1590/2359-3997000000224.
Shieh A, Chun R, Ma C, Witzel S, Meyer B, Rafison B
J Clin Endocrinol Metab. 2016; 101(8):3070-8.
PMID: 27192696
PMC: 4971338.
DOI: 10.1210/jc.2016-1871.
Serra M, Ryan A
Horm Metab Res. 2016; 48(8):497-502.
PMID: 26882050
PMC: 4987199.
DOI: 10.1055/s-0042-101550.
Vitamin D3 supplementation in HIV infection: effectiveness and associations with antiretroviral therapy.
Coelho L, Cardoso S, Luz P, Hoffman R, Mendonca L, Veloso V
Nutr J. 2015; 14:81.
PMID: 26283663
PMC: 4538921.
DOI: 10.1186/s12937-015-0072-6.
Success of Standard Dose Vitamin D Supplementation in Treated Human Immunodeficiency Virus Infection.
Lake J, Hoffman R, Tseng C, Wilhalme H, Adams J, Currier J
Open Forum Infect Dis. 2015; 2(2):ofv068.
PMID: 26125033
PMC: 4462892.
DOI: 10.1093/ofid/ofv068.
Low vitamin D levels have become less common in primary hyperparathyroidism.
Walker M, Cong E, Lee J, Kepley A, Zhang C, McMahon D
Osteoporos Int. 2015; 26(12):2837-43.
PMID: 26084258
PMC: 4793903.
DOI: 10.1007/s00198-015-3199-6.
Vitamin D in Primary Hyperparathyroidism: Effects on Clinical, Biochemical, and Densitometric Presentation.
Walker M, Cong E, Lee J, Kepley A, Zhang C, McMahon D
J Clin Endocrinol Metab. 2015; 100(9):3443-51.
PMID: 26079779
PMC: 4570160.
DOI: 10.1210/jc.2015-2022.
Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism.
Cesareo R, Di Stasio E, Vescini F, Campagna G, Cianni R, Pasqualini V
Osteoporos Int. 2014; 26(4):1295-302.
PMID: 25524023
DOI: 10.1007/s00198-014-3000-2.
Lower vitamin D levels in surgical hyperparathyroidism versus thyroid patients.
Lindeman B, Pesce C, Tsai H, Somervell H, Umbricht C, Kowalski J
Am Surg. 2014; 80(5):505-10.
PMID: 24887732
PMC: 4362715.
Management of hypovitaminosis D in patients with primary hyperparathyroidism.
Rathi M, Gonzalez S, Wright D, Ellis N, Peacey S
J Endocrinol Invest. 2014; 37(5):467-71.
PMID: 24515299
DOI: 10.1007/s40618-014-0056-y.
1,25-dihydroxyvitamin D and the vitamin D receptor gene polymorphism Apa1 influence bone mineral density in primary hyperparathyroidism.
Christensen M, Apalset E, Nordbo Y, Varhaug J, Mellgren G, Lien E
PLoS One. 2013; 8(2):e56019.
PMID: 23418495
PMC: 3572149.
DOI: 10.1371/journal.pone.0056019.
BMD improvements after operation for primary hyperparathyroidism.
Rolighed L, Vestergaard P, Heickendorff L, Sikjaer T, Rejnmark L, Mosekilde L
Langenbecks Arch Surg. 2012; 398(1):113-20.
PMID: 23132462
DOI: 10.1007/s00423-012-1026-5.
Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada.
Hanley D, Cranney A, Jones G, Whiting S, Leslie W, Cole D
CMAJ. 2010; 182(12):E610-8.
PMID: 20624868
PMC: 2934850.
DOI: 10.1503/cmaj.080663.
Biochemical effects of calcifediol supplementation in mild, asymptomatic, hyperparathyroidism with concomitant vitamin D deficiency.
Isidro M, Ruano B
Endocrine. 2009; 36(2):305-10.
PMID: 19598008
DOI: 10.1007/s12020-009-9211-1.
Vitamin D therapy.
Geller J, Adams J
Curr Osteoporos Rep. 2008; 6(1):5-11.
PMID: 18430394
DOI: 10.1007/s11914-008-0002-z.
Cholecalciferol (vitamin D3) therapy and vitamin D insufficiency in patients with chronic kidney disease: a randomized controlled pilot study.
Chandra P, Binongo J, Ziegler T, Schlanger L, Wang W, Someren J
Endocr Pract. 2008; 14(1):10-7.
PMID: 18238736
PMC: 2654595.
DOI: 10.4158/EP.14.1.10.
Current pharmacological options for the management of primary hyperparathyroidism.
Vestergaard P
Drugs. 2006; 66(17):2189-211.
PMID: 17137403
DOI: 10.2165/00003495-200666170-00004.
A very high incidence of low 25 hydroxy-vitamin D serum concentration in a French population of patients with primary hyperparathyroidism.
Boudou P, Ibrahim F, Cormier C, Sarfati E, Souberbielle J
J Endocrinol Invest. 2006; 29(6):511-5.
PMID: 16840828
DOI: 10.1007/BF03344140.